Live in the Nax Market site in the heart of New York City's Times Square, this is fast money.

Here's what's on tap tonight.

Strong prognosis.

Pharma surging for a second straight day following the president's drug pricing deal.

Is this the kickstart the stalled sector has needed?

We'll debate that.

Plus, a binging backlash why Elon Musk is joining the call to cancel Netflix, the impact on the

stock and the story behind the cancel culture drama. And later, Intel's latest lifeline giving shares

a lift, how Nike's results are leaving other shoemakers in the dust and why one firm is ready to hang up

on AT&T. I'm Melissa Lee. Come to you live from studio at the NASDAQ on The Death Tonight. Tim Seymour, Karen Feinerman, Dan Nathan, and Guy Adami. Well, the S&B 500 closing at an all-time high once again, crossing above the 6,700 level for the first time ever. The NASAC and Dow also closing in on positive territory today. More on the markets coming up, but first we've got to get It's a big day two of the big pharma breakout, biogen surging more than 10% today. More on the markets coming up. But first, we've got to get to day two of the big

pharma breakout. Biogen surging more than 10% today. Eli Lilly, Merck, Moderna, Pfizer, also building

on yesterday's big gains. These bullish moves coming after President Trump announced a drug

pricing deal with Pfizer yesterday, and there's speculation that there's more to come. The S&P

health care UTF has been underperforming the broader market this year, but could new deals help

pump life into a trade that's been barely showing a pulse? Karen, you actually made a trade

based on yesterday's game. Yes, the PPH, which was the VanEx Big Cap Pharma. You know,

it's been interesting. This space has been under pressure for so long.

And, you know, the multiples, while they were cheap up here, they just kept getting cheaper and cheaper and cheaper.

We know Tim and my Pfizer.

My Pfizer.

My Pfizer now.

We are all Pfizer's now.

...